Literature DB >> 8760046

FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells.

M D Rokaw1, M E West, P M Palevsky, J P Johnson.   

Abstract

The immunosuppressants cyclosporin A (CyA), FK-506, and rapamycin (RAP) have multiple actions on target cells that appear to be mediated by interaction of drug-binding protein complexes. Both FK-506 and CyA, but not RAP, inhibit the Ca2(+)-dependent phosphatase, calcineurin, and in so doing have been found to inhibit Na(+)-K(+)-ATPase activity in various nephron segments. Of interest, FK-506 and RAP, but not CyA, are bound by the steroid receptor-associated FK-506-binding heat shock protein of 56 kDa, HSP56. To determine the physiological effect of this interaction on a steroid-mediated phenomenon, the effect of these agents on steroid-mediated Na+ transport in A6 cells was investigated. Aldosterone stimulation of Na+ transport and Na(+)-K(+)-ATPase activity are significantly inhibited by prolonged incubation with FK-506 and RAP. Although CyA inhibits basal Na(+)-K(+)-ATPase activity, it has no effect on aldosterone-induced Na+ transport or the aldosterone-induced increase in Na(+)-K(+)-ATPase activity. FK-506 inhibits the aldosterone-induced synthesis of G alpha i-3 protein but has no effect on glucocorticoid receptor number as quantified by Western blotting. The results suggest that FK-506 and RAP inhibit steroid-mediated Na+ transport at some pretranslational site. The common interaction of these agents with the steroid receptor-associated HSP56 might account for these findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760046     DOI: 10.1152/ajpcell.1996.271.1.C194

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Fludrocortisone as a new tool for managing tubulopathy after pediatric renal transplantation: a series of cases.

Authors:  Justine Bacchetta; Odile Basmaison; Anne-Laure Leclerc; Aurélia Bertholet-Thomas; Pierre Cochat; Bruno Ranchin
Journal:  Pediatr Nephrol       Date:  2014-06-09       Impact factor: 3.714

2.  Mitochondria-targeted cardioprotection in aldosteronism.

Authors:  Atta U Shahbaz; German Kamalov; Wenyuan Zhao; Tieqiang Zhao; Patti L Johnson; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2011-01       Impact factor: 3.105

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.